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Merkel cell carcinoma (MCC) was given a such name after the German histopathologist Friedrich Merkel, who first in 
1875, described the Merkel cells, as small round or oval basophilic cells located at the end of nerve axons and within 
the basal layer of the epidermis. The current agreement about the function of Merkel cells they are associated with the 
nerve terminals acting as mechanoreceptors. MCC is a clinically aggressive uncommon, cutaneous neuroendocrine 
neoplastic tumour with a high mortality rate. Clinically may be presented as a painless, rapidly growing, dome-shaped 
red or purplish nodule. Usually in a sun-exposed area of the head and neck or upper limbs. Tremendous effort has 
been done in the last few years for a better understanding of the pathogenesis behind the MCC and the discovery 
of the Merkel cell polyomavirus suggests another clue to its pathogenesis. The expression of both epithelial and 
neuroendocrine immunohistochemical markers in the malignant cells, gives the tumour a unique feature that helps 
differentiate this neoplasm from other entities.
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Introduction
Merkel cell carcinoma (MCC) is a highly aggressive neu-
roendocrine carcinoma of the skin. In spite it is a rare tumour, 
its incidence is increasing. It is known to have high rates of 
recurrence and distant metastasis. MCC is a frequently lethal 
skin cancer with a higher mortality (33%) than melanoma 
(15%) [1]. This cancer is known with rapid progression course 
and poor prognosis. British National Cancer Intelligence 
Network 10 year incidence rate for rare skin cancer across 
English Cancer Registries (1999–2008) Report revealed evi-
dence for increasing standardised incidence rates of Merkel 
cell carcinoma (0.1 to 0.2 per 100,000 population). Risk fac-
tors include, polyomavirus, UV light, immunosuppression 
and presence of other cancers as lymphomas. 
Historical background
 Freidrich Sigmund Merkel, a German histopatholo-
gist, first described the Merkel cells in 1875 using animal 
modules. They are clear-staining cells at the dermo-epi-
dermal junction were near myelinated nerve fibers, they 
acted as mechanoreceptors, other Merkel cells that have no 
contact with nerve terminals appear to have an endocrine 
function [2]. Intriguingly, three years later, the term Merkel 
cell was born by a young anatomist Robert Bonnet who 
later worked with Dr. Merkel [3]. The first human cases was 
first reported in 1972 by Toker, who was born in South Africa 
and worked as a Professor of Pathology at University of 
Maryland School of Medicine in Baltimore, USA. He used the 
term “trabecular carcinoma” of the skin to describe a poorly 
differentiated carcinoma of the dermis and subcutaneous 
tissue [4, 5], this is why some papers called this disease as 
Toker Tumour.
Epidemiology, risk factors & pathogenesis
MCC is a frequently lethal skin cancer with a higher mor-
tality (33%) than melanoma (15%) [1]. This cancer is known 
with rapid progression course and poor prognosis. British 
National Cancer Intelligence Network 10 year incidence 
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rate for rare skin cancer across English Cancer Registries 
(1999–2008) Report revealed evidence for increasing stand-
ardised incidence rates of Merkel cell carcinoma (0.1 to 0.2 
per 100,000 population). Risk factors include, polyomavirus, 
UV light, immunosuppression and presence of other cancers 
as lymphomas.
The increased incidence of the disease could be due to 
actual incidence increase. Other factors are blamed as grow-
ing aged population, increased sun exposure (Tropical Holi-
day Factor), tanning salons, advancement in immunohisto-
chemical diagnostic techniques together with better regis-
tration facilities. MCC occurs more often among elderly fare 
skin patients with somewhat more commonly in males [6]. 
Most common on sun‐exposed areas or artificial light [4, 10, 11]. 
Predominantly occurred in head and neck area (more than 
50%) followed by limbs (40%). The rest 10% reported in the 
trunk [4]. Non-sun exposed area MCC also has been reported 
as vulva [12], tongue [13] and gluteal area [14]. In the year 
2008, a team from University of Pittsburgh, USA, came with 
new break through related to the pathogenesis of MCC. 
It is related to Merkel cell polyomavirus (MCV or MCPyV), 
reports mentioned that it is present in 80% of cases. It is 
a small novel polyomavirus with a genome consisting of 
double-stranded DNA. Thus, MCV may be a contributing 
factor in the pathogenesis of MCC [6, 15, 16]. The MCPyV 
large T antigen contains MCC tumor-specific mutations that 
withdraw its replication capability, however perpetuate 
its oncogenic functions, and the small t antigen encour-
ages an environment propitious for carcinogenesis [17, 18]. 
Immuno-suppression increases the relative risk of MCC es-
pecially with HIV, solid‐organ transplant patients as well 
as autoimmune diseases [19–22]. Also patients with lym-
phoproliferative disorders as chronic lymphocytic leukaemia 
(CLL) have an increased risk of MCC [23].Other cancers as-
sociated with MCC are skin squamous cell carcinoma, basal 
cell carcinoma, malignant melanoma, Hodgkin lymphoma, 
Non-Hodgkin Lymphoma [24].
There are reports about primary MCC arises in the breast 
skin [25], however there is a case of coexistence of MCC with 
a breast cancer [26]. The reported observations support the 
existence of shared risk factors for MCC and other cancers. It 
is reported that the Merkel cell polyomavirus has a potential 
oncogenic effect [1, 15, 16], is it possible that, this virus also 
related to the other cancers. This is a need for more research 
to be done in this field. 
Clinical picture
Clinical picture could be a reddish blue, firm, non‐ten-
der, nodular mass that has grown rapidly over a few weeks 
or even for months, this may ulcerate. They metastasise to 
lymph nodes (55%), liver, lung and bones (34–49%) with 
a local recurrence rate of 40–44% after primary treatment. 
Rarer sites of metastasis has been described in testis [27], 
mesentery [28] and tibia [29]. Secondary disease is an indica-
tive feature for poor prognosis.
American Joint Committee on Cancer (AJCC) and the In-
ternational Union for Cancer Control (UICC) in the year 2010 
recommended MCC TNM Staging System. This was based on 
retrospective study included 5823 from the National Cancer 
Database registry [30], see Table I. 
Histology
The microscopic features may show Merkel cells with 
scanty cytoplasm, a small dark polygonal nucleus with 
granular chromatin and a high mitotic rate [29]. Generally 
speaking, the histological features of MCC are similar to 
those of various other tumours, such as metastatic small 
cell lung carcinoma, blastic haematological malignancies 
of skin/soft tissue, and melanoma. Usually presented as 
composed of strands or nests of uniform, small round cells 
with scanty cytoplasm, round to oval nucleus with powdery 
dispersed chromatin, and inconspicuous nucleoli [32], see 
Figures 1 and 2.
Immunohistochemistry
A distinctive histochemical feature of MCC, is the ex-
pression of both neuroendocrine and epithelial markers. 
It is positive for CK-20, which is a sensitive marker for MCC 
and present in 90–100% of cases. As CK-20 is positive in 
some cases of extra-pulmonary small cell lung carcinoma 
(SCLC) it is essential that, the immunological study should 
include TTF-1 (Thyroid Transcription Factor-1), which ex-
pressed in 80–100% of SCLC but negative in MCC [33, 34]. 
CD56 is a sensitive marker for MCC but not specific [35]. 
Other immunohistochemical studies are need to confirm 
the diagnosis as the markers may coincide. One of those 
markers is CK-7(Cytokeratin-7) may be positive in carcinoid 
and basal cell carcinoma but negative in MCC. S-100 protein 
is another marker used to differentiate between malignant 
melanoma (usually positive) and MCC (usually negative) 
[36]. Synaptophysin is a trans-membrane channel protein 
of small pre-synaptic vesicles. MCC consistently shows posi-
tive immunoreactions to synaptophysin [37]. A combined 
features of cutaneous squamous cell carcinoma (SCC) and 
MCC noticed in some cases. As the MCC component often 
exists within the dermis, and not in the epidermis, dermis 
including biopsies should be carried out when evaluating 
potential NMSC (Non- Melanomatous Skin Cancer). This 
enables, not to miss an unrevealed deadly neuroendocrine 
element with a too superficial shave, causing delays in di-
agnosis and management of this aggressive and often fatal 
tumor [38]. Quantitative polymerase chain reaction (PCR) 
assay we used to detect MCPyV (Merkel Cell polyomavirus) 
DNA, this was found to be positive in 80% of cases [6, 16]. 
Most of the recurrence appears within the first six to 12 
months after the initial diagnosis [25]. Initial management 
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TX Primary tumor cannot be assessed TX
T0 No evidence of primary tumor T0
Tis In situ primary tumor Tis
T1 Less than or equal to 2 cm maximum tumor dimension T1
T2 Greater than 2 cm but not more than 5 cm maximum tumor dimension T2
T3 Over 5 cm maximum tumor dimension T3
T4 Primary tumor invades bone, muscle, fascia, or cartilage T4
REGIONAL LYMPH NODES (N)
NX Regional lymph nodes cannot be assessed NX
N0 No regional lymph node metastasis N0
Nodes negative by clinical exam*(no pathologic exam performed) cN0
Nodes negative by pathologic exam pN0
N1 Metastasis in regional lymph node(s) N1
Micrometastasis** N1a
Macrometastasis*** N1b
N2 In transit metastasis N2
*Clinical detection of nodal disease may be via inspection, palpation and/or imaging
**Micrometastasis are diagnosed after sentinel or elective lymphadenectomy
***Macrometastases are defined as clinically detectable nodal metastases confirmed  
by therapeutic lymphadenectomy or needle biopsy
****In transit metastasis: a tumor distinct from the primary lesion and located either  
1) between the primary lesion and the draining regional lymph nodes or  
2) distal to the primary lesion
DISTANT METASTASIS (M)
M0 No distant metastasis (no pathologic M0; use clinical M to complete stage group)
M1 Metastasis beyond regional lymph nodes M1
M1a Metastasis to skin, subcutaneous tissues or distant lymph nodes M1a
M1b Metastasis to lung M1B
M1c Metastasis to all other visceral sites M1C
ANATOMIC STAGE • PROGNOSTIC GROUPS
CLINICAL PATHOLOGIC
Group T N M Group T N M
0 Tis N0 M0 0 Tis N0 M0
IB T1 N0 M0 IA T1 pN0 M0
IIB T2/3 N0 M0 IIA T2/3 pN0 M0
IIC T4 N0 M0 IIC T4 N0 M0
IIIB Any T cN1/N1b/N2 M0 IIIA Any T N1a M0
IV Any T Any N M1 IIIB Any T N1b/N2 M0
n IV Any T Any N M1
Note: Isolated tumor nodes should be considered positive nodes Note: Isolated tumor nodes should be considered positive nodes
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of the patients has a significant impact on disease progres-
sion. This depends on the time of the first presentation 
and initiating the targeted treatment, this factor is decisive 
to disease prognosis. Immuno-histochemistry staining for 
cytokeratin 20 needed for diagnosis.
Treatment
Current optimal treatment is with radical surgical exci-
sion of the primary tumour, sentinel lymph node biopsy, 
± regional lymph node dissection, radiotherapy, chemo-
therapy & immunotherapy [10, 39, 40].
Advanced Merkel-cell carcinoma often responds to chem-
otherapy, but responses are transient. Interfering with the 
programmed death 1 (PD-1) immune inhibitory pathway is 
of interest, because MCC often express PDL1, and MCPyV-
-specific T cells express PD-1. Using Pembrolizumab to block 
PD-1 revealed objective response rate of 56%. Responses were 
observed in patients with virus-positive tumours and those 
with virus-negative tumours [41]. MCC response to Nivolumab 
immunotherapy in the current clinical trials is promising [42].
Future
A trial of Pazopanib for Merkel cell skin cancer (UKM- 
-CC‐01). Phase 2 Recruitment started: 01/12/2012 and ended: 
09/02/2016, currently awaiting results.
Conclusion
MCC is an aggressive cutaneous malignancy. The inci-
dence of MCC is on the rise, and steadily ascend awareness 
along with moving forward in immuno-histochemistry stain-
ing techniques have greatly facilitated the diagnosis. The 
published reports heightened awareness of the association 
between MCC and other cancers. Further research is needed 
to explore this issue. Also there is a need to implement 
evidence‐based management guidelines for MCC patients, 
especially that the inadequate initial management of many 
patients may contribute to the unfavourable disease pro-
gression and prognosis.
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